Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
暂无分享,去创建一个
E. Giné | A. López-Guillermo | L. Colomo | E. Campo | E. González-Barca | G. Gutiérrez-García | T. Cardesa-Salzmann | F. Climent | S. Mercadal | J. Mate | J. Sancho | L. Arenillas | S. Serrano | L. Escoda | S. Martínez | A. Valera | Antonio Martínez | P. Jares | M. Pinyol | A. García-Herrera | A. Martínez-Trillos | N. Villamor | A. Martı́nez-Trillos | Alexandra Valera | A. Martínez‐Trillos
[1] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[2] M. Pike,et al. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. , 1973, Biometrics.
[3] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[4] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[5] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[6] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[7] Emili Montserrat,et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.
[8] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] S. Barrans,et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. , 2004, Blood.
[10] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[11] R. Rosenquist,et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis , 2005, Modern Pathology.
[12] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Giorgio Cattoretti,et al. PRDM1/Blimp‐1 is expressed in human B‐lymphocytes committed to the plasma cell lineage , 2005, The Journal of pathology.
[14] P. Gaulard,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Yasodha Natkunam,et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.
[16] P. de Paepe,et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[19] C. Gisselbrecht,et al. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] C J L M Meijer,et al. Immunohistochemical profiling based on Bcl‐2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma , 2006, The Journal of pathology.
[21] Carl Blomqvist,et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. , 2007, Blood.
[22] W. Chan,et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Antonio Martínez,et al. Expression of the Interferon Regulatory Factor 8/ICSBP-1 in Human Reactive Lymphoid Tissues and B-cell Lymphomas: A Novel Germinal Center Marker , 2008, The American journal of surgical pathology.
[24] L. Staudt,et al. Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.
[25] B. Cheson. New response criteria for lymphomas in clinical trials. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] W. Chan,et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. , 2008, Blood.
[27] L. Staudt,et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A Rosenwald,et al. Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) , 2007, Journal of Clinical Pathology.
[29] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[30] A. López-Guillermo,et al. Activation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications. , 2009, The American journal of pathology.
[31] L. Sehn. Early detection of patients with poor risk diffuse large B-cell lymphoma , 2009, Leukemia & lymphoma.
[32] Kai Fu,et al. A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy , 2009, Clinical Cancer Research.
[33] C. Copie-Bergman,et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L. Staudt,et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. , 2009, Blood.
[35] Michael Hummel,et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. , 2010, Blood.
[36] W. Wilson,et al. Novel disease targets and management approaches for diffuse large B-cell lymphoma , 2010, Leukemia & lymphoma.
[37] J. Greer,et al. Primary bone lymphoma: a set of unique problems in management , 2010, Leukemia and Lymphoma.
[38] Kai Fu,et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] D.,et al. Regression Models and Life-Tables , 2022 .